Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of... Supplemental Figure Legends Supplemental Figure S1. Equivalent binding of anti-CTLA-4 isotypes to cell surface CTLA-4. - - Anti-CTLA-4 isotypes were tested for binding to cells constitutively expressing CTLA-4 (58a b mCTLA-4-CD3ζ). Supplemental Figure S2. Serum concentrations of anti-CTLA-4 isotypes in C57BL/6 mice. For details see Supplemental Table S2. Supplemental Figure S3. Representative FACS plots for peripheral regulatory T cells. Supplemental Figure S4. A. Representative FACS plots for intratumoral regulatory T cells. B. Kinetics of intratumoral Treg reduction following anti-CTLA-4 treatment. MC38 tumor bearing C57BL/6 mice (d7 after implantation) were treated with a single dose of 200 ug of isotype control mIgG1, anti-CTLA-4 9D9-IgGD265A or anti-CTLA-4 9D9-IgG2a, and tumors were isolated on d1, d2 or d5 after treatment. Tumors and spleen were harvested, manually dissociated into single cell suspensions, and stained for flow cytometry as in Figure 3. Supplemental Figure S5. Isotype-dependent recruitment of MDSCs and IL-1α production. 2x10 MC38 colon tumor cells were implanted subcutaneously into C57BL/6 mice. At day 7 post-implantation, tumor bearing mice were randomized and received 3 doses of antibody by intraperitoneal injection (10 mg/kg) every 3 days. On day 15 post-implantation, tumors were harvested, manually dissociated into single cell suspensions, and numbers of MDSCs + http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Immunology Research Unpaywall

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

Download PDF
2 pages

Loading next page...
 
/lp/unpaywall/anti-ctla-4-antibodies-of-igg2a-isotype-enhance-antitumor-activity-hVV4HEPWM0

References (50)

Publisher
Unpaywall
ISSN
2326-6066
DOI
10.1158/2326-6066.cir-13-0013
Publisher site
See Article on Publisher Site

Abstract

Supplemental Figure Legends Supplemental Figure S1. Equivalent binding of anti-CTLA-4 isotypes to cell surface CTLA-4. - - Anti-CTLA-4 isotypes were tested for binding to cells constitutively expressing CTLA-4 (58a b mCTLA-4-CD3ζ). Supplemental Figure S2. Serum concentrations of anti-CTLA-4 isotypes in C57BL/6 mice. For details see Supplemental Table S2. Supplemental Figure S3. Representative FACS plots for peripheral regulatory T cells. Supplemental Figure S4. A. Representative FACS plots for intratumoral regulatory T cells. B. Kinetics of intratumoral Treg reduction following anti-CTLA-4 treatment. MC38 tumor bearing C57BL/6 mice (d7 after implantation) were treated with a single dose of 200 ug of isotype control mIgG1, anti-CTLA-4 9D9-IgGD265A or anti-CTLA-4 9D9-IgG2a, and tumors were isolated on d1, d2 or d5 after treatment. Tumors and spleen were harvested, manually dissociated into single cell suspensions, and stained for flow cytometry as in Figure 3. Supplemental Figure S5. Isotype-dependent recruitment of MDSCs and IL-1α production. 2x10 MC38 colon tumor cells were implanted subcutaneously into C57BL/6 mice. At day 7 post-implantation, tumor bearing mice were randomized and received 3 doses of antibody by intraperitoneal injection (10 mg/kg) every 3 days. On day 15 post-implantation, tumors were harvested, manually dissociated into single cell suspensions, and numbers of MDSCs +

Journal

Cancer Immunology Research – Unpaywall

Published: Apr 9, 2013

There are no references for this article.